Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Comment by septbugleon Mar 25, 2017 4:17pm

141 Views

Post# 26030939

RE:RE:RE:New Report

I would have to agree ithink we should trade above .25 once we start dosing patients.It is also an open lable trial so we could get progress reports along the way.In the first trial they seen regression in the first 6 weeks. They do evaluate after 3 months so there should be an update at that piont we just need to get started hopefully next week then maybee people will regain some confidence in the new ceo. GLTA

Bullboard Posts

The deep connection between mining and First Nations in Canada